<DOC>
	<DOCNO>NCT01640951</DOCNO>
	<brief_summary>CAIN457A2304E1 extension study two ongoing phase III study , CAIN457A2304 CAIN457A2307 ( core study ) . This extension study plan collect two year long-term safety , tolerability efficacy data secukinumab fixed interval regimen retreatment start relapse regimen . All subject complete Week 52 CAIN457A2304 Week 40 CAIN457A2307 eligible participate extension study . Week 40 CAIN457A2307 study end maintenance visit ( EOM ) equivalent Week 52 ( EOM ) CAIN457A2304 core study . Therefore , subject enter CAIN457A2304E1 study receive 52 week treatment previous study / study . In extension study , prefilled syringe ( PFS ) liquid formulation secukinumab use .</brief_summary>
	<brief_title>Extension Study Secukinumab Prefilled Syringes Subjects With Moderate Severe Chronic Plaque-type Psoriasis Completing Preceding Secukinumab Phase III Studies</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects must able understand communicate investigator comply requirement study must give write , sign date informed consent study relate activity perform . Where relevant , legal representative also sign inform consent accord local law regulation . 2 . Subjects complete Week 52 study CAIN457A2304 complete Week 40 study CAIN457A2307 3 . Subjects expect benefit participation extension study , assess subject investigator 1 . A protocol deviation core study accord investigator prevent meaningful analysis extension study individual subject 2 . Ongoing use prohibit psoriasis nonpsoriasis treatment . Time period last use prohibit treatment core study first dose study drug extension study . 3 . Subjects expect exposed undue safety risk participate trial 4 . Current severe progressive uncontrolled disease judgment investigator render subject unsuitable trial 5 . Plans administration live vaccine study period 6 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 10 mIU/mL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>